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vaccine candidate. A recombinant N-terminal part of SpyCEP (CEP) was expressed and puriﬁed. AntiCEP
antibodieswere found toneutralize the IL-8 cleavingactivityof SpyCEP.CEP-immunizedmicehad reduced
bacterial dissemination from focal S. pyogenes intramuscular infection and intranasal infection. We also
identiﬁed a functional SpyCEP-homolog protease SeCEP, expressed by the equine pathogen Streptococcus
equi, which was able to cleave both human and equine IL-8. CEP-immunized mice also demonstrated
reduced bacterial dissemination from S. equi intramuscular infection. Therefore immunization against
ectio
pyCEP
accine SpyCEP may provide prot
. Introduction
Group A streptococcus (GAS) diseases are responsible for
00,000 deaths globally per year, mostly attributed to rheumatic
ever and rheumatic heart disease, although cases of invasive
AS account for around 160,000 deaths [1]. There is currently
o licensed vaccine for GAS. The surface M protein has been the
ain focus of GAS vaccine research and the most successful, but
evelopment has been hindered by the sheer number of differ-
nt M-serotypes (>120 M-types) and cross reactivity with human
roteins that may result in immune sequelae [2,3]. Current M
rotein-based vaccines use peptides derived from the conserved
-terminus [4,5] ormultivalent peptides from the hypervariable N-
erminus [6–8]. There have beenmany approaches to identify other
uitable targets (reviewed in [9]). A whole genome bioinformatic
nd proteomic technique identiﬁed Spy0416 as a potential candi-
ate, second only to M protein in conferring protection from death
aused by anM23 strain [10]. Spy0416 is identical to the Streptococ-
us pyogenes cell envelope proteinase SpyCEP, and is responsible
or cleaving and inactivating interleukin 8 (IL-8) [11]. SpyCEP is a
ighly conserved cell wall anchored subtilisin-like protease that is
lso released from the bacterial surface.
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In this study, the potential for SpyCEP vaccination to protect
against bacterial dissemination fromboth an intramuscular soft tis-
sue infection and an upper respiratory tract infection caused by a
clinically relevant M81 S. pyogenes strain, was evaluated in mice.
To determine whether SpyCEP represented a broad acting vac-
cine target we also identiﬁed functional SpyCEP homologs in the
Lanceﬁeld group C strains Streptococcus equi and Streptococcus
zooepidemicus. S. equi (S. equi subsp. equi) is a highly infectious
equine pathogen that causes Strangles, a lymphadenitis of the head
andneck resulting inabscessationandprofusenasaldischarge,with
occasional fatal dissemination to distant parts of the body (Bastard
Strangles) [12]. Cross-protectivity of SpyCEP immunization against
S. equi disease was also assessed. The work demonstrated that
immunity to SpyCEP can prevent severe infection dissemination of
two streptococcal species, and suggests potential for cell envelope
proteases (CEPs) as vaccine candidates for all streptococcal species
that express homologous proteases.
2. Methods
2.1. Bacterial strains
S. pyogenes strain H292 (M81) was isolated from a patient with
rapidly progressive necrotizing fasciitis and bacteremia. Genome
Open access under CC BY license.strains S. equi strain 4047 and S. zooepidemicus strain H70 were
obtained from Andrew Waller (Animal Health Institute, Newmar-
ket, UK). All streptococcal strains were cultured on Columbia horse
blood agar or in Todd-Hewitt broth (THB) (Oxoid, Basingstoke,
UK) at 37 ◦C, 5% CO2 without shaking. Escherichia coli were cul-
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ured in Luria-Bertani broth (Oxoid) with 50g/ml ampicillin
Sigma–Aldrich, Dorset, UK)
.2. Recombinant CEP protein
A portion of the SpyCEP protein (CEP) encompassing amino acid
esidues 35–587 of the pre-pro SpyCEP sequence (Genbank No.
Q413032) was cloned and expressed using the pET100 cloning
ystem (Invitrogen, Paisley, UK). This sequence includes two of the
hreeactive sites. RecombinantCEPproteinwas thennickel-column
uriﬁed according to the manufacturer’s instructions (Novagen,
ottingham, UK). Recombinant CEP was tested to ensure it had
o serine protease activity and was used to raise rabbit polyclonal
ntiCEP serum [13].
.3. Neutralizing activity of rabbit antiCEP serum
S. pyogenes H292 cell-free supernatant was co-incubated with
ng/ml human IL-8 (R&D, Abingdon, UK) and either 50% normal
abbit serum or antiCEP rabbit serum for 16h at 37 ◦C. Uncleaved
L-8 was measured by human IL-8 duoset ELISA (R&D) (which does
ot detect cleaved IL-8) and IL-8 cleaving activity due to SpyCEP
as calculated in comparison to the control (IL-8 in THB).
.4. Flow cytometry
Approximately 1×108 S. pyogenes H292 cells were harvested
rom an overnight culture and ﬁxed for two hours at room tem-
erature in 3% paraformaldehyde. After washing twice in PBS, cells
ere then incubated in 50l normal rabbit serumor rabbit antiCEP
erum, diluted 1 in 10 in PBS, for 30min at 37 ◦C. Cells were then
ashed twice in PBS-0.1% Tween20 before incubating with 50l
f FITC labeled goat anti-rabbit IgG (Invitrogen) diluted 1 in 200 in
BS, on ice. Flow cytometry was performed on a FACSCalibur (Bec-
on Dickinson, Oxfordshire, UK) counting 40,000 events. Data were
nalyzed using FlowJo software (Tree Star Inc.)..5. Immunization challenge
Eight-ten week old female BALB/c mice (Charles River, Margate,
K)weighing20–24gwere immunized intramuscularlywith50g
ig. 1. (A) Flow cytometric demonstration of rabbit antiCEP serum binding to surface Sp
howed increased ﬂuorescence compared to those stainedwith normal rabbit serum (shad
xperimental triplicates are shown. (B) Rabbit antiCEP serum neutralizes SpyCEP. Wester
ng human IL-8 in the presence of normal rabbit serum (NRS) or antiCEP rabbit serum (a7 (2009) 4923–4929
of recombinant CEP protein emulsiﬁed 1:1 in Freund’s complete
adjuvant (Sigma–Aldrich, Poole, UK). Two booster immunizations
were given at days 14 and 21 in Freund’s incomplete adjuvant
(Sigma–Aldrich). A control group of mice were immunized with
PBS and adjuvant. Tail bleeds were obtained on day 20. On day 28,
mice were infected with S. pyogenes strain H292 or S. equi strain
4047. All animal procedures were conducted in accordance with
UK Home Ofﬁce guidance and approval. For intramuscular infec-
tion,mice received∼5×106 S. pyogenes and∼5×107 S. equidirectly
into thigh muscle. For upper respiratory tract infection, mice were
anaesthetized with isoﬂurane and ∼3×108CFU of S. pyogenes was
allowed to be inhaled by placing 10l of bacterial suspension onto
eachnostril. After 24hof infection,micewere euthanizedandblood
was takenbycardiacpuncture. Spleen, liver and infected thighmus-
cle were excised from mice infected intramuscularly, individually
weighed, and homogenized in PBS. For S. equi infection, only spleen
and thighwas taken. Lung, nose and nasal-associated lymphoid tis-
sue (NALT) in addition to spleen and liver, were taken from mice
infected intranasally and homogenized in PBS. End points for infec-
tion were bacterial dissemination to blood, spleen or liver and IL-6
levels, measured by ELISA duoset (R&D), at 24h. Infection dissem-
ination was determined by culturing known quantities of blood,
liver and spleen. Viable CFU were measured on horse blood agar.
2.6. Western blotting of culture supernatant and cell wall
fractions
Streptococcal strains were grown to early (EL, A6000.2–0.3), mid
(ML, A6000.5) and late (LL, A6000.7–0.9) log phases of growth. Cell
wall preparationsweremadeusinganenzymaticmethoddescribed
by Biswas et al. [14]. Culture supernatant and cell wall extract pro-
teinswere separated by10%Bis-Tris SDS-PAGEgels (Invitrogen) and
immunoblotted using rabbit antiCEP serum. Blots were developed
using goat anti-rabbit-HRP and the ECL system (GE Healthcare,
Chalfont St Giles, UK).2.7. IL-8 cleavage SDS PAGE and immunoblotting
Cell-free bacterial culture supernatant was incubated at 37 ◦C
overnight with 100g/ml human IL-8 (R&D) or 100g/ml equine
IL-8 (Perbio, Northumberland, UK). IL-8 was detected by 12% Bis-
yCEP using S. pyogenes strain H292. Cells stained with antiCEP (unshaded peaks)
ed gray peaks) indicating binding of antiCEP antibodies to surface expressed SpyCEP.
n blot for human IL-8. Culture supernatant from S. pyogenes was co-incubated with
ntiCEP). IL-8 incubated with THB alone (THB) was included as a control.
cine 27 (2009) 4923–4929 4925
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Fig. 2. Immunization ofmicewith CEP induces antiCEP antibodies. Serumwas taken
on day 20 from mice immunized with recombinant CEP (solid line, squares) or PBS
blood, liver or spleen occurred in 6/8 control mice but only 2/8
CEP-immunized mice. Exact bacterial counts of spleen and liver
are shown in Fig. 4. Two mice from each group were bacteremic.
Although numbers in groups were small the data suggest that
spread from the initial infection site was reduced by immunizationC.E. Turner et al. / Vac
ris SDS-PAGE (Invitrogen) stained with Colloidal Blue staining kit
Invitrogen) or immunoblotted with anti-human IL-8 HRP labeled
ntibody (R&D) and streptavidin (R&D).
.8. Measurement of antibody responses to CEP
To measure murine antibody response to recombinant CEP an
LISA-basedassaywas employed. Plateswere coatedwith20g/ml
EP and bound mouse IgG was detected with HRP conjugated goat
nti-mouse IgG.
.9. Mass spectrometry
S. pyogenes and S. equi culture supernatants containing SpyCEP
r SeCEP respectively, were concentrated by 100kDa centrifu-
al ﬁlter devices (Amicon, Co Durham, UK). Chemokines human
L-8 (R&D) and equine IL-8 (Perbio) were suspended in acetoni-
rile:water:formic acid (20:80:0.1) anddiluted to40ng/l in50mM
mmonium bicarbonate and co-incubated with 1l of concen-
rated supernatant at 37 ◦C for 18h. Digested and undigested
uman IL-8 and equine IL-8were chromatographed on a C4 picofrit
olumn (0.075×10mm) (New Objective, supplied by Presearch,
asingstoke, UK) and analyzed by electrospray MS using an LTQ
ontrapMS (ThermoFisher Scientiﬁc, Hemel Hempstead, UK); other
onditions were as described previously [11].
.10. Statistical analysis
Comparative statistics were performed using non-parametric
nalysis with GraphPad Prism version 4.03 for Windows, Graph-
ad Software, San Diego California USA. Chi-squared analysis was
erformed where groups of 10 or more were used.
. Results
.1. Polyclonal antiCEP antibodies recognize SpyCEP and are
eutralizing
Rabbit antiCEP serum was able to recognize and bind to SpyCEP
xpressed on the surface of whole S. pyogenes H292 cells as deter-
inedbyﬂowcytometry (Fig. 1A). This antiCEP serumwas also able
o neutralize the IL-8 cleaving activity of SpyCEP present in H292
ulture supernatant (Fig. 1B). This suggested that recombinant CEP
rotein induced antibodieswith the potential to provide protection
rom S. pyogenes infection.
.2. CEP immunization reduced disease severity and
issemination in intramuscular S. pyogenes infection
Mice immunized with recombinant CEP had a consistently high
erum IgG response, even at 1:10,000 dilution, compared with
ontrols (Fig. 2). Following intramuscular challenge, infection dis-
emination to blood, liver or spleen occurred in 8/10 control mice
ut only 1/10 CEP-immunized mice (2 =9.899; p<0.001). Exact
acterial counts of spleen and liver are shown in Fig. 3. Only one
ouse, from the control group, was bacteremic. Bacterial load in
he thigh muscle was unaffected by CEP vaccination, possibly due
o the short duration of the experiment (24h) (Controls: median
.8×106 CFU/mg, range 1.0×106 to 1.0×107 CFU/mg. Immunized:
edian 6.8×106 CFU/mg, range 1.0×106 to 2.4×107 CFU/mg).
Serum IL-6, a marker of disease severity, was lower in theEP-immunized mice (median 91.3pg/ml, range undetectable-
263.0pg/ml) compared to the control mice (median 314.7pg/ml,
ange 9.8–776.4pg/ml; p=0.0433). Taken together, spread of dis-
ase and disease severity were reduced by immunity to SpyCEP in
his infection model.(dashed line, diamonds). Serum obtained from normal unimmunizedmice was also
included (dotted line, triangles). CEPspeciﬁc IgGwasmeasuredusinganELISA-based
assay in serum diluted in PBS. Data show the mean of sera from 6 mice (±standard
deviation).
3.3. CEP immunization reduced dissemination in intranasal S.
pyogenes infection
Following intranasal challenge, infection dissemination toFig. 3. After challenge intramuscularly with 6×106 CFU/mouse of S. pyogenes, 8/10
control mice demonstrated bacterial dissemination to liver (ﬁlled circles) or spleen
(open circles), while only 1/10 CEP-immunized mice demonstrated dissemination
(2 = 9.899; p<0.001). Exact bacterial counts per 10mg of organ from each mouse
are shown; 3 mice in the control group showed dissemination to both liver and
spleen. Median is represented by a horizontal bar. N.D: not detected.
4926 C.E. Turner et al. / Vaccine 2
Fig. 4. After challenge intranasally with 3.1×108 CFU/mouse of S. pyogenes 6/8 con-
trol mice demonstrated bacterial dissemination to liver (ﬁlled circles) or spleen
(open circles), while only 2/8 CEP-immunized mice demonstrated dissemination.
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Nxact bacterial counts per 10mg of organ from eachmouse are shown; 4mice in the
ontrol group and 1 mouse in the immunized group showed dissemination to both
iver and spleen.N=8 per group. Median is represented by a horizontal bar. N.D: not
etected.
ith SpyCEP. Immunization with CEP did not, however, inﬂuence
arriage of S. pyogenes in the nose and nasal-associated lymphoid
issue during the 24h experiment (Table 1). Serum IL-6 was no dif-
erent between CEP-immunized mice (median 311.3pg/ml, range
7.0pg/ml–1.4ng/ml) and control mice (median 120.8pg/ml, range
ndetectable-28.5ng/ml).
.4. Homologous proteases in S. equi and S. zooepidemicus
We hypothesized that vaccination against SpyCEP could also
rotect against other streptococcal infections. A search of other
treptococcal genomes revealed that the SpyCEP gene (cepA) has
any homologs in other species but particularly in the Lanceﬁeld
roup C species S. equi and S. zooepidemicus. S. equi (Strain 4047,
anger Institute) cell envelope proteinase (SeCEP) and S. zooepi-
emicus (Strain H70, Sanger Institute) cell envelope proteinase
SzoCEP) are 98% identical to each other by BlastP analysis and
re 59% identical (74% similar) to SpyCEP. SpyCEP, SeCEP and Szo-
EP all encode N-terminal signal peptides (predicted by SignalP
.0 server) from residues 1–34 and a C-terminal LPSTG cell-wall
nchoring motif for secretion of the enzyme to the cell surface and
ttachment to the cell wall (Fig. 5). The three catalytic domains
ypical of cell envelope proteinase containing the active residues
spartic acid, histidine and serine, have a high degree of sequence
imilarity. Using rabbit antiCEP serum, SeCEP was detected in the
ulture supernatant and cell wall extract of S. equi (Fig. 6A). Szo-
EP could not be detected in culture supernatant or cell wall
xtract of S. zooepidemicusdespitehomology tobothSeCEPandSpy-
EP, suggesting poor expression in this strain. SeCEP was detected
hroughout exponential growth as a ∼160kDa protein which is
able 1
acterial CFU from lung, nose and NALT tissue following intranasal infection with S. pyoge
Controls
Infected CFUa
ung 7/8 1.0×107 (2.0×101 to 1.9×107)
ose 8/8 3.3×106 (1.0×105 to 9.5×106)
ALT 8/8 1.0×109 (5.8×106 to 1.7×1010)
a Lung and nose: CFU/10mg, NALT: CFU/NALT.7 (2009) 4923–4929
approximately the same size as the fully processed SpyCEP. A sec-
ondary band was also detected at ∼70kDa, not present in the
SpyCEP Western blot but it is unclear what this band corresponds
to. Preimmune serum blots were blank (not shown).
Cleavage of human IL-8 by SeCEP and SzoCEP was measured by
ELISA which demonstrated approximately 90% degradation of IL-8
by SeCEP that could be inhibited by antiCEP serum (MannWhitney,
p=0.0286). S. zooepidemicus demonstrated limited cleavage of IL-8
thatwas unaffected by the presence of antiCEP serum (Fig. 6B). Spe-
ciﬁc IL-8 degradation by SeCEP was also detected by Western blot
(Fig. 6C). Both ELISAmeasurement of IL-8 degradation andWestern
blotting for IL-8 demonstrated that SeCEP could degrade human
IL-8 but SzoCEP did not. Degradation of human IL-8 appeared to
be speciﬁc (Fig. 6D); SpyCEP- and SeCEP-cleaved IL-8 had approxi-
mately the same molecular weight. In contrast, cleavage of equine
IL-8 by both SeCEP and SzoCEPwas observed by SDS PAGE (Fig. 6D).
The site of cleavage of human IL-8 and equine IL-8 by SeCEP
was conﬁrmedbymass spectrometry (Fig. 7). SeCEP cleavedhuman
1–72IL-8 (Mav, 8387.00) at the samepositionas SpyCEP;between59Q
and 60R to form 1–59IL-8 (Mav, 6829.0). Cleavage of equine 1–74IL-8
(Mav, 8377.49)bySeCEPoccurred in theanalogouspositionbetween
59Q and 60I, to form 1–59IL-8 (Mav, 6711.90). SpyCEP was also con-
ﬁrmed to cleave equine IL-8 in the same position.
3.5. Immunization with recombinant CEP prevents dissemination
of S. equi infection
Following intramuscular challenge with S. equi dissemina-
tion to spleen occurred in 10/10 control mice but only 6/10
immunized mice (2 =5.0; p=0.0127). Immunized mice had an
average of 100-fold less S. equi load in the spleen than con-
trol mice (Mann Whitney, p<0.0001) (Fig. 8). S. equi numbers in
the thigh were unaffected by CEP vaccination (Controls: median
7×107, range (4.2–9.2)×107, Immunized: median 6.3×107, range
(2.6–9.2)×107). Serum IL-6 did not reﬂect the reduced bacterial
load and remained similar between the two groups (Controls:
median 515.7pg/ml, range 177.6–1794pg/ml, Immunized: median
552.3pg/ml, range 153.6–1528pg/ml).
4. Discussion
SpyCEP is the S. pyogenes cell envelope proteinase that is able
to cleave and inactivate IL-8 and other CXC chemokines [11,15].
The surface location of SpyCEP and the high degree of conser-
vation between isolates [15,16] makes it an ideal vaccine target.
Indeed a whole genome proteomic and bioinformatic study iden-
tiﬁed SpyCEP (Spy0416) as a potential protective target promoting
survival from an intranasal M23 infection, second only to M pro-
tein [10]. Studies in mice have demonstrated that SpyCEP plays
an important role in disease [13,17] suggesting that neutralization
of SpyCEP would be detrimental to the pathogen, although other
studies could not conﬁrm this [15,18]. In these preliminary studies
we have demonstrated that immunization against SpyCEP induces
neutralizing immunity andappears topreventdisseminationofdis-
ease from the site of infection. This was true for infection with S.
pyogenes and S. equi.
nes.
Immunized
Infected CFU
7/8 1.4×106 (0.2×101 to 1.5×107)
8/8 4.2×106 (6.0×105 to 9.8×106)
7/8 3.0×109 (5.0×106 to 2.2×1010)
C.E. Turner et al. / Vaccine 27 (2009) 4923–4929 4927
Fig. 5. SeCEP and SzoCEP are homologous to SpyCEP. Identical residues are shaded black and similar residues are shaded gray. Putative signal peptides span residues 1–34.
At the C-terminus all three proteins encode a sortase processing LPXTG motif which precedes a hydrophobic region and a positively charged tail for cell wall anchorage. The
subtilase active residues aspartic acid, histidine and serine (indicated by (*)) and surrounding residues show 81% identity.
Fig. 6. SeCEP and SzoCEP have IL-8 cleaving activity. (A)Western blot of culture supernatant or cell wall extract from S. pyogenes, S. equi and S. zooepidemicus to detect SpyCEP,
SeCEP and SzoCEP respectively using antiCEP serum at different phases of growth (EL: early log, ML: mid log, LL: late log). Expression of SeCEP was similar to SpyCEP. (B) IL-8
cleaving activity of S. equi and S. zooepidemicus late log phase culture supernatant in the presence of normal rabbit serum (white bars) or rabbit antiCEP serum (black bars).
Percentage of IL-8 cleaved was calculated in comparison to the IL-8 control (IL-8 incubated with THB alone). Data represent the mean of four separate experiments measured
in duplicate (+standard deviation). (C)Western blot for human IL-8. Culture supernatants of S. equi or S. zooepidemicuswere incubatedwith 5ng of human IL-8 in the presence
of normal rabbit serum (NRS) or rabbit antiCEP serum (antiCEP). IL-8 incubated in THB alone was used as a control. (D) Colloidal blue stained SDS PAGE for human IL-8 (left)
or equine IL-8 (right) after incubation with culture supernatant from S. pyogenes, S. equi and S. zooepidemicus. IL-8 incubated in THB alone was used as a control.
4928 C.E. Turner et al. / Vaccine 27 (2009) 4923–4929
F uine
T vertic
f
m
w
t
a
g
s
s
s
e
C
s
n
i
u
t
t
T
e
n
o
a
t
s
t
t
F
1
s
i
m
t
rig. 7. Human and equine IL-8 cleavage. Alignment and BOXSHADE of human and eq
he point of cleavage of both IL-8 molecules by SpyCEP and SeCEP is indicated by a
Despite a global need, there is currently no licensed vaccine
or GAS. The highly abundant surface M protein has been the
ost promising target but there have been problems associated
ith it. There are over 120 different M-types based on the N-
erminal hypervariable region; antibodies directed to this region
re opsonising but type speciﬁc [19]. Other regions of M protein
enerate antibodies that either are not opsonising or demon-
trate cross reactivity with host tissue that may result in post
treptococcal immune sequelae. SpyCEP does not demonstrate any
equencebased serotype speciﬁcity and, althoughabsolute levels of
xpression may vary, all clinical strains tested demonstrated Spy-
EP activity that could be inhibited by antiCEP antibodies [16]. It
eems likely that SpyCEP would be immunogenic in humans, since
eutralizing antibodies to the protease are generated by natural
nfection, being found in pooled human intravenous immunoglob-
lin [Turner et al., unpublished].
We expressed and puriﬁed a 552aa portion of the SpyCEP pro-
ein spanning residues 35–587aa which begins immediately after
he signal peptide and includes two of three catalytic domains.
his recombinant protein (CEP) was administered intramuscularly,
mulsiﬁed in adjuvant, and produced high systemic SpyCEP immu-
ity. Immunization with CEP resulted in reduced dissemination
f disease both from an intramuscular soft tissue infection and
n intranasal upper respiratory infection. Clearance from the ini-
ial site of infection was not affected by vaccination although the
tudy was designed to assess the effect on invasive disease and
herefore the infection course was necessarily short. Full evalua-
ion of CEP as a vaccine for S. pyogenes pharyngitis and carriage
ig. 8. After challenge intramuscularlywith 5×107 CFU/mouse of S. equi strain 4047
0/10 control mice demonstrated bacterial dissemination to liver (ﬁlled circles) or
pleen (open circles), while only 6/10 CEP-immunized mice demonstrated dissem-
nation (2 = 5.0; p=0.0127). Exact bacterial counts per 10mg of organ from each
ouse are shown. Control mice also had higher bacterial counts in the spleen than
he immunized group (Mann Whitney, p<0.0001). N=10 per group. Median is rep-
esented by a horizontal bar. N.D: not detected.IL-8 where identical residues are shaded black and similar residues are shaded gray.
al arrow.
will require testing in an appropriatemodel of pharyngeal/tonsillar
carriage.
S. equi and S. zooepidemicus both encode SpyCEP homologs that
in this work have been shown to be functional homologs. S. zooepi-
demicus (S. equi subsp. zooepidemicus) is a mucosal opportunistic
pathogen of a number of animals. Rarely it can also cause severe
infections in humans such as bacteremia, meningitis and nephritis
[20,21]. Despite carrying the gene for SzoCEP, protein expression
and human IL-8 degrading activity was not detected in this strain.
Cleavage of equine IL-8 was, however, detected suggesting that
expression of SzoCEP is low in this strain. In contrast, SeCEP pro-
duced by S. equi was highly expressed throughout exponential
growth both at the cell surface and released into the culture super-
natant in a similar manner to SpyCEP produced by S. pyogenes.
SeCEP cleaved both human IL-8 and equine IL-8 and cleavage of
human IL-8 was inhibited by antiCEP serum conﬁrming SeCEP spe-
ciﬁc proteolysis. The comparable expression pattern and function
of SeCEP to SpyCEP suggested that the role of SeCEP in infectionmay
be similar to SpyCEP, although the disease Strangles ismore suppu-
rative than that seen in clinical S. pyogenes disease. Immunization
of mice with CEP reduced disease dissemination of S. equi from an
intramuscular soft tissue infection. Although it did not completely
inhibit infection dissemination, the disease produced by S. equiwas
more severe in mice than that caused by S. pyogenes. Strangles is
predominantly a disease of the equine upper respiratory tract and
lymph node system hence a full evaluation of CEP as a vaccine is
required in an equine setting using intranasal administration.
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